Cargo Therapeutics (Cargo Therapeutics) Debt-to-EBITDA : -0.21 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cargo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.64 Mil. Cargo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $26.57 Mil. Cargo Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-135.83 Mil. Cargo Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.21.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cargo Therapeutics's Debt-to-EBITDA or its related term are showing as below:

CRGX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69 Med: -0.56 Max: -0.24
Current: -0.24

During the past 3 years, the highest Debt-to-EBITDA Ratio of Cargo Therapeutics was -0.24. The lowest was -0.69. And the median was -0.56.

CRGX's Debt-to-EBITDA is ranked worse than
100% of 275 companies
in the Biotechnology industry
Industry Median: 1.36 vs CRGX: -0.24

Cargo Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Cargo Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Debt-to-EBITDA Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.56

-0.69

-0.31

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial				-	-0.05	-0.02	-0.23	-0.21

Competitive Comparison of Cargo Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Cargo Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cargo Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's Debt-to-EBITDA falls into.

Cargo Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cargo Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.278	+	26.263)	/	-92.851
	=	-0.31

Cargo Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.637	+	26.568)	/	-135.828
	=	-0.21

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Cargo Therapeutics (NAS:CRGX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cargo Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics (Cargo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing strategy are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. Their lead program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics (Cargo Therapeutics) Headlines

From GuruFocus

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

By Marketwired • 04-15-2024